Published in Stroke on May 28, 2009
Standardized prehospital treatment of stroke. Dtsch Arztebl Int (2011) 2.21
Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke. Ann Emerg Med (2015) 1.99
Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke (2012) 1.76
RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res (2012) 1.45
Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci U S A (2011) 1.32
Shaping plasticity to enhance recovery after injury. Prog Brain Res (2011) 1.20
Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res (2010) 1.17
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med (2010) 1.02
Neural bases of recovery after brain injury. J Commun Disord (2011) 1.00
Electroacupuncture Pretreatment as a Novel Avenue to Protect Brain against Ischemia and Reperfusion Injury. Evid Based Complement Alternat Med (2012) 1.00
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J Vasc Interv Neurol (2012) 0.97
Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions. Int J Mol Sci (2013) 0.95
NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death? Acta Physiol (Oxf) (2011) 0.94
Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion. J Cereb Blood Flow Metab (2013) 0.91
Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci U S A (2012) 0.90
Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med (2010) 0.90
Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One (2014) 0.89
Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke. Stroke (2012) 0.88
Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients. Stroke Res Treat (2011) 0.87
Imaging techniques for acute ischemic stroke: nice gadgets or essential tools for effective treatment? Neuroradiology (2009) 0.87
Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol (2014) 0.86
Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. Transl Stroke Res (2011) 0.85
Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J Cereb Blood Flow Metab (2013) 0.84
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol (2017) 0.84
Optogenetic Approaches to Target Specific Neural Circuits in Post-stroke Recovery. Neurotherapeutics (2016) 0.84
Recanalization and Reperfusion Therapies of Acute Ischemic Stroke: What have We Learned, What are the Major Research Questions, and Where are We Headed? Front Neurol (2014) 0.82
The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol (2011) 0.82
Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res (2013) 0.82
Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res (2013) 0.81
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res (2010) 0.81
Imaging and treatment of patients with acute stroke: an evidence-based review. AJNR Am J Neuroradiol (2013) 0.81
Current understanding of TRPM7 pharmacology and drug development for stroke. Acta Pharmacol Sin (2012) 0.79
Aneurysmal subarachnoid hemorrhage models: do they need a fix? Stroke Res Treat (2013) 0.78
Mild acute ischaemic stroke--the case for thrombolytic therapy. Nat Rev Neurol (2013) 0.77
A novel mechanism of neuroprotection: Blood glutamate grabber. J Cereb Blood Flow Metab (2015) 0.77
Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice. PLoS One (2015) 0.77
Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset. Neurohospitalist (2012) 0.75
Angiographic and Clinical Factors Related with Good Functional Outcome after Mechanical Thrombectomy in Acute Cerebral Artery Occlusion. J Korean Neurosurg Soc (2015) 0.75
Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012. Int J Stroke (2013) 0.75
Electroacupuncture-induced neuroprotection against focal cerebral ischemia in the rat is mediated by adenosine A1 receptors. Neural Regen Res (2017) 0.75
Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke. Front Neurol (2017) 0.75
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 13.37
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol (2006) 10.51
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke (2008) 2.57
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43
Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab (2008) 1.86
Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke (2007) 1.72
Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke (2007) 1.62
Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med (2008) 1.54
Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke (2010) 1.53
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke (2008) 1.44
Clinical scores for predicting recurrence after transient ischemic attack or stroke: how good are they? Stroke (2013) 1.43
Thrombolysis in stroke despite contraindications or warnings? Stroke (2013) 1.40
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res (2013) 1.36
Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke (2007) 1.29
The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke (2008) 1.18
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR. Stroke (2009) 1.09
A statistical model for the dependence between progression-free survival and overall survival. Stat Med (2009) 1.08
Diffusion-weighted MR imaging in acute ischemia: value of apparent diffusion coefficient and signal intensity thresholds in predicting tissue at risk and final infarct size. AJNR Am J Neuroradiol (2004) 1.06
Geography, structure, and evolution of diffusion and perfusion lesions in Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE). Stroke (2009) 1.01
On the variability of covariate adjustment. experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials. Control Clin Trials (2002) 1.01
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J (2010) 0.99
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). Int J Stroke (2012) 0.88
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window? Stroke (2006) 0.88
A new nonparametric approach for baseline covariate adjustment for two-group comparative studies. Biometrics (2008) 0.87
Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiency. Hum Mol Genet (2012) 0.87
Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum Mol Genet (2013) 0.85
Optimal outcome measures for detecting clinical benefits of early reperfusion: insights from the DEFUSE Study. J Stroke Cerebrovasc Dis (2008) 0.85
Association of early CT abnormalities, infarct size, and apparent diffusion coefficient reduction in acute ischemic stroke. AJNR Am J Neuroradiol (2004) 0.84
Images in neurology. Scattered cerebral microbleeds due to cardiac myxoma. Arch Neurol (2009) 0.84
Selection for delayed intravenous alteplase treatment based on a prognostic score. Int J Stroke (2013) 0.75
Exploration of time-course combinations of outcome scales for use in a global test of stroke recovery. Int J Stroke (2013) 0.75
How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach. Stat Med (2011) 0.75